Giá của Viking Therapeutics, Inc. là bao nhiêu (VKTX)

Giá của Viking Therapeutics, Inc. (VKTX) là $34.49

Mũ thị trường của Viking Therapeutics, Inc. là gì (VKTX)

Giới hạn thị trường của Viking Therapeutics, Inc. (VKTX) là $4.02B

Lịch sử giá Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

Năm	Hiệu suất
2026 (TTM)	-9.08%
2025	-20.83%
2024	152.59%
2023	215.71%
2022	16.84%
2021	-21.08%
2020	-20.48%
2019	-10.51%
2018	130.53%
2017	246.93%
2016	-60.36%
2015	0.00%

Năm

Hiệu suất

2026 (TTM)

-9.08%

2025

-20.83%

2024

152.59%

2023

215.71%

2022

16.84%

2021

-21.08%

2020

-20.48%

2019

-10.51%

2018

130.53%

2017

246.93%

2016

-60.36%

2015

0.00%

Công ty	Giá cổ phiếu	Thay đổi 1năm%	Quốc gia
Vertex Pharmaceuticals Incorporated VRTX.US	$548.57	41.68%	US
Argenx SE ARGX.US	$1.05K	47.98%	NL
CSL Limited CSL.AX	$121.62	-12.98%	AU
Moderna, Inc. MRNA.US	$146.13	490.91%	US
Lonza Group AG LONN.SW	$764.47	6.25%	CH

Công ty

Giá cổ phiếu

Thay đổi 1năm%

Quốc gia